Timothy Craig, DO
Allergy & Immunology · Hershey, PANPI 1609825306
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $348,245 of the $564,019 with a category attached, or 61.7%. 29 manufacturers reported payments, led by CSL Behring at 52.1% of the total. Among allergy & immunology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 639 payments — averaging $882.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$294K
- Takeda Pharmaceuticals U.S.A., Inc.$102K
- Grifols USA, LLC$33K
- Biocryst Pharmaceuticals, Inc.$27K
- Biocryst US Sales Co., LLC$18K
- Regeneron Healthcare Solutions, Inc.$14K
- plus $77K from 23 others
Across 465 payments — averaging $3088.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$764K
- Shire North American Group Inc$190K
- Takeda Pharmaceuticals U.S.A., Inc.$161K
- GSK$161K
- Ionis Pharmaceuticals, Inc.$57K
- Biocryst Pharmaceuticals, Inc.$49K
- plus $54K from 4 others
What the payments were for
- Consulting fees$154,06527%
- Speaking & faculty fees$348,24562%
- Travel & lodging$46,8378%
- Food & beverage$14,7383%
- Education$1340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 287 | $293,986 |
| Takeda Pharmaceuticals U.S.A., Inc. | 95 | $101,992 |
| Grifols USA, LLC | 46 | $32,694 |
| Biocryst Pharmaceuticals, Inc. | 40 | $26,758 |
| Biocryst US Sales Co., LLC | 27 | $17,797 |
| Regeneron Healthcare Solutions, Inc. | 10 | $13,837 |
| Shire North American Group Inc | 12 | $11,528 |
| Ionis Pharmaceuticals, Inc. | 8 | $10,914 |
| Sanofi | 17 | $9,742 |
| Boehringer Ingelheim | 2 | $7,902 |
| GSK | 12 | $7,707 |
| Pharming Healthcare, Inc. | 15 | $6,633 |
| Novartis | 11 | $6,491 |
| Insmed, Inc. | 20 | $5,271 |
| Spark Therapeutics, Inc. | 4 | $3,764 |
| Cycle Pharmaceuticals Inc | 2 | $1,768 |
| Bristol Myers Squibb | 1 | $1,120 |
| Hexal AG | 1 | $1,013 |
| Grifols Shared Services North America, Inc. | 2 | $904 |
| Biomarin Pharmaceutical Inc. | 2 | $422 |
| Vifor Pharma, Inc. | 4 | $386 |
| Amgen(2 entities) | 5 | $358 |
| Genentech USA, Inc. | 4 | $263 |
| AstraZeneca | 3 | $199 |
| Regeneron | 3 | $172 |
| Blueprint Medicines Corporation | 2 | $161 |
| Genentech, Inc. | 2 | $158 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $49 |
| Dermavant Sciences, Inc. | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$564,019 in reported general payments places this provider in the 95th percentile of 175 allergy & immunology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 37 | $1,817,640 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 47 | $518,783 |
| HaegardaC1 Esterase Inhibitor | 11 | $407,463 |
| GlassiaAlpha-1-Proteinase Inhibitor | 14 | $260,997 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 30 | $193,139 |
| Breo ElliptaFluticasone/Vilanterol | 41 | $19,961 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $16,756 |
| Epinephrine | 18 | $4,640 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 31 | $4,316 |
| Levocetirizine Dihydrochloride | 11 | $1,281 |
| Montelukast Sodium | 37 | $1,026 |
| Azelastine Hcl | 24 | $516 |
| Fluticasone Propionate | 42 | $509 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $410 |
| Omeprazole | 12 | $245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro, Glassia | $101,992 | $2,078,63751 claims |
| CSL BehringHaegarda, Hizentra | $293,986 | $600,60241 claims |
| Grifols USA, LLCProlastin C | $32,694 | $518,78347 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $7,707 | $36,71755 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 175 allergy & immunology providers in Pennsylvania.
Other allergy & immunology in Hershey
- Drew WeissmanPhiladelphia$12.8M
- Eric SchenkelBethlehem$845K
- Sergei BelenkyPittsburgh$775K
- Sandra GawchikUpland$390K
- Anthony RooklinGlen Mills$319K
- Corinna BowserNarberth$229K
- Shailen ShahCollegeville$183K
- Michael PremattaHavertown$168K
- Donald HarperMechanicsburg$142K
- Kumar PatelTarentum$124K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.